Lifecore Biomedical Analyst Ratings
Lifecore Biomedical Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/01/2023 | 14.07% | Stephens & Co. | $8 → $9 | Maintains | Equal-Weight |
| 06/02/2023 | 39.42% | Barrington Research | $10 → $11 | Maintains | Outperform |
| 05/24/2023 | 26.74% | Barrington Research | $8 → $10 | Maintains | Outperform |
| 03/21/2023 | 1.39% | Barrington Research | $10 → $8 | Maintains | Outperform |
| 03/20/2023 | 1.39% | Barrington Research | $10 → $8 | Maintains | Outperform |
| 03/20/2023 | -74.65% | Stephens & Co. | $11 → $2 | Downgrades | Overweight → Equal-Weight |
| 03/17/2023 | 39.42% | Stephens & Co. | → $11 | Reiterates | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 09/01/2023 | 14.07% | 斯蒂芬斯公司 | $8→$9 | 維護 | 等重 |
| 06/02/2023 | 39.42% | 巴靈頓研究公司 | $10→$11 | 維護 | 跑贏大盤 |
| 2023年05月24日 | 26.74% | 巴靈頓研究公司 | $8→$10 | 維護 | 跑贏大盤 |
| 03/21/2023 | 1.39% | 巴靈頓研究公司 | $10→$8 | 維護 | 跑贏大盤 |
| 03/20/2023 | 1.39% | 巴靈頓研究公司 | $10→$8 | 維護 | 跑贏大盤 |
| 03/20/2023 | -74.65% | 斯蒂芬斯公司 | $11→$2 | 評級下調 | 超重→等重 |
| 03/17/2023 | 39.42% | 斯蒂芬斯公司 | →$11 | 重申 | →超重 |
What is the target price for Lifecore Biomedical (LFCR)?
Lifecore Biomedical(LFCR)的目標價格是多少？
The latest price target for Lifecore Biomedical (NASDAQ: LFCR) was reported by Stephens & Co. on September 1, 2023. The analyst firm set a price target for $9.00 expecting LFCR to rise to within 12 months (a possible 14.07% upside). 7 analyst firms have reported ratings in the last year.
斯蒂芬斯公司於2023年9月1日報道了Lifecore Biomedical(納斯達克代碼：LFCR)的最新目標價。這家分析公司將目標價定為9.00美元，預計LFCR將在12個月內上漲至14.07%。去年有7家分析公司公佈了評級。
What is the most recent analyst rating for Lifecore Biomedical (LFCR)?
Lifecore Biomedical(LFCR)的最新分析師評級是多少？
The latest analyst rating for Lifecore Biomedical (NASDAQ: LFCR) was provided by Stephens & Co., and Lifecore Biomedical maintained their equal-weight rating.
斯蒂芬斯公司提供了對Lifecore Biomedical(納斯達克代碼：LFCR)的最新分析師評級，Lifecore Biomedical維持其同等權重的評級。
When is the next analyst rating going to be posted or updated for Lifecore Biomedical (LFCR)?
Lifecore Biomedical(LFCR)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Lifecore Biomedical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Lifecore Biomedical was filed on September 1, 2023 so you should expect the next rating to be made available sometime around September 1, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與Lifecore Biomedical的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Lifecore Biomedical的上一次評級是在2023年9月1日提交的，所以你應該預計下一次評級將在2024年9月1日左右的某個時候提供。
Is the Analyst Rating Lifecore Biomedical (LFCR) correct?
分析師對Lifecore Biomedical(LFCR)的評級正確嗎？
While ratings are subjective and will change, the latest Lifecore Biomedical (LFCR) rating was a maintained with a price target of $8.00 to $9.00. The current price Lifecore Biomedical (LFCR) is trading at is $7.89, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Lifecore Biomedical(LFCR)評級維持不變，目標價在8.00美元至9.00美元之間。Lifecore Biomedical(LFCR)目前的交易價格為7.89美元，超出了分析師的預測區間。